Gincy George
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gincy George has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
- Mieke Van Hemelrijck
King's College London London UK
11 shared publications M. Van Hemelrijck
5 shared publicationsMieke Van Hemelrijck
Transforming cancer OUtcomes through Research (TOUR), School of Cancer & Pharmaceutical Sciences, King’s College London
5 shared publicationsSarah Rudman
Medical Oncology, Guy’s and St Thomas NHS Foundation Trust
5 shared publicationsHans Garmo
Translational Oncology and Urology Research, King's College London, London, UK
4 shared publications- Beth Russell
Transforming Cancer Outcomes Through Research (TOUR) King's College London London UK
3 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
A structured approach to formulating high-impact research questions in clinical and translational science
A well-formulated research question is the cornerstone of any high-quality clinical and translational study. It shapes study design, guides methodological choices, and determines whether findings can meaningfully improve health outcomes. Poorly formulated research questions can therefore be associated with methodological weaknesses, infeasible study designs, and reduced research impact. Developing a well-defined research question begins with understanding the research landscape and requires careful balancing of existing evidence and theoretical rationale. More importantly, a strong research question often emerges from areas of uncertainty, inconsistency or an unmet clinical need within current clinical practice. This article explores a stepwise approach to developing robust research questions by incorporating literature appraisal, topic refinement, clear objectives setting, and consideration of structured frameworks such as T0–T4 continuum, feasible, interesting, novel, ethical, relevant, manageable, appropriate, potentially impactful, systematic and population, intervention or exposure, comparator, outcomes and the timeframe. It highlights how researchers can identify knowledge gaps, avoid common pitfalls, and ensure alignment with clinical needs, practical feasibility, and ethical standards. By integrating these elements, investigators can develop a rigorous and relevant research question resulting in a study that is methodologically feasible and positioned to drive advances across the translational continuum.
- 13 November 2026
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
Open AccessA structured approach to formulating high-impact research questions in clinical and translational science
A well-formulated research question is the cornerstone of any high-quality clinical and translational study. It shapes study design, guides methodological choices, and determines whether findings can meaningfully improve health outcomes. Poorly formulated research questions can therefore be associated with methodological weaknesses, infeasible study designs, and reduced research impact. Developing a well-defined research question begins with understanding the research landscape and requires careful balancing of existing evidence and theoretical rationale. More importantly, a strong research question often emerges from areas of uncertainty, inconsistency or an unmet clinical need within current clinical practice. This article explores a stepwise approach to developing robust research questions by incorporating literature appraisal, topic refinement, clear objectives setting, and consideration of structured frameworks such as T0–T4 continuum, feasible, interesting, novel, ethical, relevant, manageable, appropriate, potentially impactful, systematic and population, intervention or exposure, comparator, outcomes and the timeframe. It highlights how researchers can identify knowledge gaps, avoid common pitfalls, and ensure alignment with clinical needs, practical feasibility, and ethical standards. By integrating these elements, investigators can develop a rigorous and relevant research question resulting in a study that is methodologically feasible and positioned to drive advances across the translational continuum.
- Open Access
- 3 November 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 2008061
Drug repurposing and treatment optimisation in oncology: regulatory challenges and policy priorities
Drug repurposing and treatment optimisation are increasingly important strategies to improve cancer outcomes by making better use of existing therapies. Drug repurposing involves identifying new clinical indications for approved or abandoned medicines, while treatment optimisation focuses on refining how established therapies are used within their licensed indications, for example, through dose, duration, or sequencing modifications. Although both approaches aim to maximise patient benefit and are supported by extensive clinical experience, they face distinct and shared regulatory challenges. We examine why current regulatory and legislative frameworks remain poorly aligned with the objectives, risk profiles, and evidentiary needs of drug repurposing and treatment optimisation studies. Drawing on illustrative case studies in oncology, including aspirin and metformin repurposing, immunotherapy optimisation, and regulatory initiatives such as Project Optimus, we demonstrate how regulatory systems designed primarily for de novo drug development create disproportionate burdens, delay evidence generation, and impede translation into routine clinical practice. The heterogeneity of evidence across prevention and treatment settings, the absence of clear licensing pathways for off-patent medicines, and the limited integration of optimisation into post-authorisation management are recurring themes. This review highlights how regulatory bottlenecks arise across the trial life cycle and how diverse treatment optimisation study designs could better address patient-centred outcomes. We propose that proportionate regulatory frameworks encompassing marketing authorisation, post-authorisation evidence generation, and reimbursement mechanisms are necessary to enable the efficient evaluation, regulatory approval, and sustainable implementation of repurposed and treatment-optimised therapies. Aligning regulation with real-world cancer care requires coordinated action from regulators, policymakers, academia, industry and clinicians to ensure that established medicines are not only approved, but used optimally to deliver meaningful, evidence-based benefit.
- 3 November 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 2008061
Open AccessDrug repurposing and treatment optimisation in oncology: regulatory challenges and policy priorities
Drug repurposing and treatment optimisation are increasingly important strategies to improve cancer outcomes by making better use of existing therapies. Drug repurposing involves identifying new clinical indications for approved or abandoned medicines, while treatment optimisation focuses on refining how established therapies are used within their licensed indications, for example, through dose, duration, or sequencing modifications. Although both approaches aim to maximise patient benefit and are supported by extensive clinical experience, they face distinct and shared regulatory challenges. We examine why current regulatory and legislative frameworks remain poorly aligned with the objectives, risk profiles, and evidentiary needs of drug repurposing and treatment optimisation studies. Drawing on illustrative case studies in oncology, including aspirin and metformin repurposing, immunotherapy optimisation, and regulatory initiatives such as Project Optimus, we demonstrate how regulatory systems designed primarily for de novo drug development create disproportionate burdens, delay evidence generation, and impede translation into routine clinical practice. The heterogeneity of evidence across prevention and treatment settings, the absence of clear licensing pathways for off-patent medicines, and the limited integration of optimisation into post-authorisation management are recurring themes. This review highlights how regulatory bottlenecks arise across the trial life cycle and how diverse treatment optimisation study designs could better address patient-centred outcomes. We propose that proportionate regulatory frameworks encompassing marketing authorisation, post-authorisation evidence generation, and reimbursement mechanisms are necessary to enable the efficient evaluation, regulatory approval, and sustainable implementation of repurposed and treatment-optimised therapies. Aligning regulation with real-world cancer care requires coordinated action from regulators, policymakers, academia, industry and clinicians to ensure that established medicines are not only approved, but used optimally to deliver meaningful, evidence-based benefit.
- Open Access
- 20 November 2025
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 10
Investigation into the clinical features, treatment patterns, and survival of older men with prostate cancer in Sweden and Belgium
- 20 November 2025
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 10
Open AccessInvestigation into the clinical features, treatment patterns, and survival of older men with prostate cancer in Sweden and Belgium
- Open Access
- 13 May 2025
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 8, 100145
Guy’s Cancer Cohort: Guy’s Cancer Centre’s Real-World Evidence Programme 5 years later
- 13 May 2025
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 8, 100145
Open AccessGuy’s Cancer Cohort: Guy’s Cancer Centre’s Real-World Evidence Programme 5 years later
- Open Access
- 4 March 2025
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 7
Guidelines and variations in patterns of GnRH analogue use in castration-resistant prostate cancer across six countries
- 4 March 2025
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 7
Open AccessGuidelines and variations in patterns of GnRH analogue use in castration-resistant prostate cancer across six countries
- Open Access
- 1 September 2023
- Published by Taylor & Francis in Pragmatic and Observational Research
- Vol. ume 14, 95-100
Real World Data Studies of Antineoplastic Drugs: How Can They Be Improved to Steer Everyday Use in the Clinic?
There is a growing interest in real world evidence when developing antineoplastic drugs owing to the shorter length of time and low costs compared to randomised controlled trials. External validity of studies in the regulatory phase can be enhanced by complementing randomised controlled trials with real world evidence. Furthermore, the use of real world evidence ensures the inclusion of patients often excluded from randomised controlled trials such as the elderly, certain ethnicities or those from certain geographical areas. This review explores approaches in which real world data may be integrated with randomised controlled trials. One approach is by using big data, especially when investigating drugs in the antineoplastic setting. This can even inform artificial intelligence thus ensuring faster and more precise diagnosis and treatment decisions. Pragmatic trials also offer an approach to examine the effectiveness of novel antineoplastic drugs without evading the benefits of randomised controlled trials. A well-designed pragmatic trial would yield results with high external validity by employing a simple study design with a large sample size and diverse settings. Although randomised controlled trials can determine efficacy of antineoplastic drugs, effectiveness in the real world may differ. The need for pragmatic trials to help guide healthcare decision-making led to the development of trials within cohorts (TWICs). TWICs make use of cohorts to conduct multiple randomised controlled trials while maintaining characteristics of real world data in routine clinical practice. Although real world data is often affected by incomplete data and biases such as selection and unmeasured biases, the use of big data and pragmatic approaches can improve the use of real world data in the development of antineoplastic drugs that can in turn steer decision-making in clinical practice.
- 1 September 2023
- Published by Taylor & Francis in Pragmatic and Observational Research
- Vol. ume 14, 95-100
Open AccessReal World Data Studies of Antineoplastic Drugs: How Can They Be Improved to Steer Everyday Use in the Clinic?
There is a growing interest in real world evidence when developing antineoplastic drugs owing to the shorter length of time and low costs compared to randomised controlled trials. External validity of studies in the regulatory phase can be enhanced by complementing randomised controlled trials with real world evidence. Furthermore, the use of real world evidence ensures the inclusion of patients often excluded from randomised controlled trials such as the elderly, certain ethnicities or those from certain geographical areas. This review explores approaches in which real world data may be integrated with randomised controlled trials. One approach is by using big data, especially when investigating drugs in the antineoplastic setting. This can even inform artificial intelligence thus ensuring faster and more precise diagnosis and treatment decisions. Pragmatic trials also offer an approach to examine the effectiveness of novel antineoplastic drugs without evading the benefits of randomised controlled trials. A well-designed pragmatic trial would yield results with high external validity by employing a simple study design with a large sample size and diverse settings. Although randomised controlled trials can determine efficacy of antineoplastic drugs, effectiveness in the real world may differ. The need for pragmatic trials to help guide healthcare decision-making led to the development of trials within cohorts (TWICs). TWICs make use of cohorts to conduct multiple randomised controlled trials while maintaining characteristics of real world data in routine clinical practice. Although real world data is often affected by incomplete data and biases such as selection and unmeasured biases, the use of big data and pragmatic approaches can improve the use of real world data in the development of antineoplastic drugs that can in turn steer decision-making in clinical practice.
- Open Access
- 15 February 2023
- Published by Wiley in Journal of Oncology
- Vol. 2023, 1-7
Use of Antiepileptic Drugs and Risk of Prostate Cancer: A Nationwide Case-Control Study in Prostate Cancer Data Base Sweden
An inverse association between use of antiepileptic drugs (AEDs) and prostate cancer (PCa) has been suggested, putatively due to the histone deacetylases inhibitory (HDACi) properties of the AEDs. In a case-control study in Prostate Cancer data Base Sweden (PCBaSe), PCa cases diagnosed between 2014 and 2016 were matched to five controls by year of birth and county of residence. AED prescriptions were identified in the Prescribed Drug Registry. Odds ratios (ORs) and 95% confidence intervals for risk of PCa were estimated using multivariable conditional logistic regression, adjusted for civil status, education level, Charlson comorbidity index, number of outpatient visits, and cumulative duration of hospital stay. Dose responses in different PCa risk categories and HDACi properties of specific AED substances were further explored. 1738/31591 (5.5%) cases and 9674/156802 (6.2%) controls had been exposed to AED. Overall, users of any AED had a reduced risk of PCa as compared to nonusers (OR: 0.92; 95% CI: 0.87–0.97) which was attenuated by adjustment to healthcare utilisation. A reduced risk was also observed in all models for high-risk or metastatic PCa in AED users compared to nonusers (OR: 0.89; 95% CI: 0.81–0.97). No significant findings were observed for dose response or HDACi analyses. Our findings suggest a weak inverse association between AED use and PCa risk, which was attenuated by adjustment for healthcare utilisation. Moreover, our study showed no consistent dose-response pattern and no support for a stronger reduction related to HDAC inhibition. Further studies focusing on advanced PCa and PCa treatments are needed to better analyse the association between use of AED and risk of PCa.
- 15 February 2023
- Published by Wiley in Journal of Oncology
- Vol. 2023, 1-7
Open AccessUse of Antiepileptic Drugs and Risk of Prostate Cancer: A Nationwide Case-Control Study in Prostate Cancer Data Base Sweden
An inverse association between use of antiepileptic drugs (AEDs) and prostate cancer (PCa) has been suggested, putatively due to the histone deacetylases inhibitory (HDACi) properties of the AEDs. In a case-control study in Prostate Cancer data Base Sweden (PCBaSe), PCa cases diagnosed between 2014 and 2016 were matched to five controls by year of birth and county of residence. AED prescriptions were identified in the Prescribed Drug Registry. Odds ratios (ORs) and 95% confidence intervals for risk of PCa were estimated using multivariable conditional logistic regression, adjusted for civil status, education level, Charlson comorbidity index, number of outpatient visits, and cumulative duration of hospital stay. Dose responses in different PCa risk categories and HDACi properties of specific AED substances were further explored. 1738/31591 (5.5%) cases and 9674/156802 (6.2%) controls had been exposed to AED. Overall, users of any AED had a reduced risk of PCa as compared to nonusers (OR: 0.92; 95% CI: 0.87–0.97) which was attenuated by adjustment to healthcare utilisation. A reduced risk was also observed in all models for high-risk or metastatic PCa in AED users compared to nonusers (OR: 0.89; 95% CI: 0.81–0.97). No significant findings were observed for dose response or HDACi analyses. Our findings suggest a weak inverse association between AED use and PCa risk, which was attenuated by adjustment for healthcare utilisation. Moreover, our study showed no consistent dose-response pattern and no support for a stronger reduction related to HDAC inhibition. Further studies focusing on advanced PCa and PCa treatments are needed to better analyse the association between use of AED and risk of PCa.
- Open Access
- 11 November 2022
- Published by Elsevier in Journal of Cancer Policy
- Vol. 34, 100370
Cancer care for Ukrainian refugees: Strategic impact assessments in the early days of the conflict
- 11 November 2022
- Published by Elsevier in Journal of Cancer Policy
- Vol. 34, 100370
Open AccessCancer care for Ukrainian refugees: Strategic impact assessments in the early days of the conflict
- 1 August 2022
- Published by Elsevier in Seminars in Oncology Nursing
- Vol. 38 (4) , 151236
Qualitative Analysis of Interviews and Focus Groups Exploring Factors Contributing to Adherence to GnRH Agonists in Men with Prostate Cancer
- 1 August 2022
- Published by Elsevier in Seminars in Oncology Nursing
- Vol. 38 (4) , 151236
Qualitative Analysis of Interviews and Focus Groups Exploring Factors Contributing to Adherence to GnRH Agonists in Men with Prostate Cancer